JP2711436B2 - Allergy remedies and allergic foods - Google Patents

Allergy remedies and allergic foods

Info

Publication number
JP2711436B2
JP2711436B2 JP7034127A JP3412795A JP2711436B2 JP 2711436 B2 JP2711436 B2 JP 2711436B2 JP 7034127 A JP7034127 A JP 7034127A JP 3412795 A JP3412795 A JP 3412795A JP 2711436 B2 JP2711436 B2 JP 2711436B2
Authority
JP
Japan
Prior art keywords
food
protease
lipase
amylase
cellulase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP7034127A
Other languages
Japanese (ja)
Other versions
JPH08225460A (en
Inventor
二郎 高木
隆博 杉田
宗彦 中村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maruho Co Ltd
Original Assignee
Maruho Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruho Co Ltd filed Critical Maruho Co Ltd
Priority to JP7034127A priority Critical patent/JP2711436B2/en
Publication of JPH08225460A publication Critical patent/JPH08225460A/en
Application granted granted Critical
Publication of JP2711436B2 publication Critical patent/JP2711436B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【産業上の利用分野】本発明は、食品の摂取に起因する
アレルギーを防止するための医薬品および食品組成物に
関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a medicine and a food composition for preventing allergy caused by ingestion of food.

【0002】[0002]

【従来の技術】アトピー性皮膚炎などの食物因子(アレ
ルゲン)に基づくアレルギー性疾患の患者数は、近年増
加の一途を辿っており、新たな文明病として注目されて
いる。この疾患の治療は、アレルゲンを摂取しないよう
食事制限を行うことが治療の基本であり、例えばコメア
レルギー患者にはグロブリンを酵素処理したコメが、牛
乳アレルギー患者には、大豆蛋白質を主原料とした疑似
乳飲料が代替食品として市販されている。
2. Description of the Related Art The number of patients with allergic diseases based on food factors (allergens) such as atopic dermatitis has been steadily increasing in recent years and is attracting attention as a new civilized disease. Treatment of this disease is based on dietary restrictions so that allergens are not ingested.For example, rice allergy patients use globulin-enzyme-treated rice, and milk allergy patients use soy protein as the main ingredient. Simulated milk drinks are marketed as alternative foods.

【0003】しかしながら、食物アレルギー患者の多く
は乳幼児や児童であり、食事による日常生活の制限が幼
い患者の情緒的発育に悪影響を及ぼすことや学校集団生
活でのいじめ問題に発展する場合等が懸念されている。
また、これらの代替食品は、製造が難しいため種類も少
なく高価であるため、食事制限の十分な実施が困難であ
る。
[0003] However, many of the food allergy patients are infants and children, and there is a concern that restriction of daily life due to diet may adversely affect the emotional development of young patients and may lead to bullying problems in school group life. Have been.
In addition, since these alternative foods are difficult to manufacture and have few types and are expensive, it is difficult to sufficiently implement dietary restrictions.

【0004】[0004]

【発明が解決しようとする課題】本発明は、食物アレル
ギー患者の乳幼児や児童が、健常人と同様な食生活を続
けることができるような抗アレルギー剤および食品組成
物を提供することを目的とする。
SUMMARY OF THE INVENTION An object of the present invention is to provide an antiallergic agent and a food composition so that infants and children of food allergies can continue their eating habits similar to healthy people. I do.

【0005】[0005]

【課題を解決するための手段】本発明者は、上記従来技
術の課題に鑑み鋭意検討を重ねた結果、プロテアーゼを
単独で、またはアレルゲンを含む食品と混合して摂取す
ることにより、食品アレルギーの症状が顕著に改善され
ることを見出した。
Means for Solving the Problems As a result of intensive studies in view of the above-mentioned problems of the prior art, the present inventor has found that by ingesting a protease alone or in combination with a food containing an allergen, food allergy can be reduced. Symptoms were found to be significantly improved.

【0006】本発明は、以下の抗アレルギー剤(第1発
明)、食品組成物(第2発明)および食品用添加剤(第
3発明)を提供するものである。
The present invention provides the following antiallergic agent (first invention), food composition (second invention), and food additive (third invention).

【0007】*第1発明 項1. プロテアーゼを有効成分とする抗アレルギー
剤。
* First invention Item 1. An antiallergic agent containing a protease as an active ingredient.

【0008】項2. (1)プロテアーゼおよび(2)
アミラーゼ、リパーゼ及びセルラーゼからなる群から選
ばれる少なくとも1種を含有してなる抗アレルギー剤組
成物。
Item 2. (1) protease and (2)
An antiallergic composition comprising at least one selected from the group consisting of amylase, lipase and cellulase.

【0009】*第2発明 項3. 蛋白質含有食品およびプロテアーゼを含むアレ
ルギー対応食品組成物。
* Second invention Item 3. An allergic food composition comprising a protein-containing food and a protease.

【0010】項4. 蛋白質含有食品および(1)プロ
テアーゼおよび(2)アミラーゼ、リパーゼ及びセルラ
ーゼからなる群から選ばれる少なくとも1種を含むアレ
ルギー対応食品組成物。
Item 4. An allergic food composition comprising a protein-containing food and (1) a protease and (2) at least one selected from the group consisting of amylase, lipase and cellulase.

【0011】*第3発明 項5. プロテアーゼを有効成分とするアレルギー対応
食品用添加剤。
* Third invention Item5. An additive for allergic foods containing protease as an active ingredient.

【0012】項6. (1)プロテアーゼおよび(2)
アミラーゼ、リパーゼ及びセルラーゼからなる群から選
ばれる少なくとも1種を含有してなるアレルギー対応食
品用添加剤。
Item 6. (1) protease and (2)
An additive for allergic foods, comprising at least one member selected from the group consisting of amylase, lipase and cellulase.

【0013】第1〜第3発明の抗アレルギー剤、食品組
成物および食品用添加剤は、特に乳幼児や児童の食品ア
レルギーの治療ないし予防に有用である。ここで、食品
アレルギーとしては、消化器系では下痢、便秘など、呼
吸器系では気管支喘息、慢性気管支炎、鼻アレルギーな
ど、皮膚系ではアトピー性皮膚炎、じんま疹、にきびな
ど、全身症状では発熱、アレルギー性疲労などが挙げら
れる。
The antiallergic agents, food compositions and food additives of the first to third inventions are particularly useful for treating or preventing food allergies of infants and children. Here, food allergies include systemic symptoms such as diarrhea and constipation in the digestive system, bronchial asthma, chronic bronchitis and nasal allergy in the respiratory system, and atopic dermatitis, urticaria and acne in the skin system. Fever, allergic fatigue and the like.

【0014】従って、本発明は、プロテアーゼを有効成
分とするアトピー性皮膚炎治療剤;およびプロテアーゼ
を有効成分とする慢性じんま疹治療剤を提供するもので
もある。
Accordingly, the present invention also provides a therapeutic agent for atopic dermatitis containing a protease as an active ingredient; and a therapeutic agent for chronic urticaria containing a protease as an active ingredient.

【0015】第1〜第3発明の「プロテアーゼ」とし
て、蛋白質を加水分解するものであれば特に制限はな
く、公知のプロテアーゼが広く利用でき、特に制限され
ないが、例えば *トリプシン、キモトリプシン、エラスターゼ、スブチ
リシン、等のセリンプロテアーゼ、 *クロストリパイン、パパインなどのチオールプロテア
ーゼ、 *サーモリシン、コラゲナーゼなどの金属プロテアー
ゼ、 *ペプシンなどのカルボキシペプチダーゼ、 *ロイシンアミノペプチダーゼ、ピロリドニルアミノペ
プチダーゼ、アミノペプチダーゼM、ジペプチジルアミ
ノペプチダーゼなどのアミノペプチダーゼ類、 *カルボキシペプチダーゼ(A、B、C、Y等)、ペニ
シロカルボキシペプチダーゼ、ジペプチジルカルボキシ
ペプチダーゼなどのカルボキシペプチダーゼ類 等が挙げられる。本発明のプロテアーゼは、これらの1
種又は2種以上からなるが、好ましくは2種以上のプロ
テアーゼを混合して用い、例えばパンクレアチンのよう
な複合酵素剤を好適に用いることができる。
The "protease" of the first to third aspects of the present invention is not particularly limited as long as it hydrolyzes a protein, and known proteases can be widely used, and are not particularly limited. For example, * trypsin, chymotrypsin, elastase, Serine proteases such as subtilisin, etc. * Thiol proteases such as clostripain and papain * Metallic proteases such as thermolysin and collagenase * Carboxypeptidases such as pepsin * Leucine aminopeptidase, pyrrolidonyl aminopeptidase, aminopeptidase M Aminopeptidases such as peptidyl aminopeptidase; * carboxypeptidases (A, B, C, Y, etc.), carboxypeptides such as penicillo carboxypeptidase, dipeptidyl carboxypeptidase, etc. Chidaze, and the like can be mentioned. The protease of the present invention
Although two or more species are used, two or more proteases are preferably used as a mixture, and a complex enzyme agent such as pancreatin can be suitably used.

【0016】好ましいプロテアーゼとしては、トリプシ
ン、キモトリプシン、カルボキシペプチダーゼ、パパイ
ンが挙げられる。
Preferred proteases include trypsin, chymotrypsin, carboxypeptidase and papain.

【0017】本発明の抗アレルギー剤、アレルギー対応
食品組成物およびアレルギー対応食品用添加剤は、各々
プロテアーゼを必須成分として含有するが、プロテアー
ゼの他にアミラーゼ、リパーゼ、セルラーゼ等の他の加
水分解酵素を含んでいてもよい。
The antiallergic agent, allergic food composition and allergic food additive of the present invention each contain a protease as an essential component. In addition to the protease, other hydrolases such as amylase, lipase, and cellulase are used. May be included.

【0018】これは、食品アレルギーのアレルゲンは、
蛋白質が大部分であるが、アレルゲンが糖蛋白やリポ蛋
白である場合には、糖や脂質を同時に加水分解すること
により、アレルゲンの分解がより促進されるためであ
る。
This is because allergens for food allergies are
This is because the protein is mostly contained, but when the allergen is a glycoprotein or a lipoprotein, the hydrolysis of the sugar or lipid simultaneously promotes the degradation of the allergen.

【0019】第1〜第3発明において、プロテアーゼと
併用されるアミラーゼとしては、α−アミラーゼ、β−
アミラーゼ及びインベルターゼが挙げられ、好ましくは
α−アミラーゼ及びβ−アミラーゼが挙げられる。
In the first to third inventions, the amylase used in combination with the protease includes α-amylase and β-amylase.
Examples include amylase and invertase, preferably α-amylase and β-amylase.

【0020】第1〜第3発明において、プロテアーゼと
併用されるリパーゼは、(モノ、ジ、トリ)グリセリ
ド、リン脂質、コレステロールエステルなどの脂質を加
水分解する公知の酵素が広く用いられ、特に限定されな
いが、例えば膵臓リパーゼ、ミルクリパーゼ、植物リパ
ーゼ、微生物リパーゼ等が挙げられ、好ましくは膵臓リ
パーゼ及び微生物リパーゼが挙げられる。
In the first to third aspects of the present invention, the lipase used in combination with the protease may be any of known enzymes that hydrolyze lipids such as (mono, di, tri) glycerides, phospholipids, and cholesterol esters. Although not mentioned, for example, pancreatic lipase, milk lipase, plant lipase, microbial lipase and the like can be mentioned, preferably pancreatic lipase and microbial lipase.

【0021】セルラーゼとしては、公知のセルラーゼが
すべて用いられ、特に限定されない。
As the cellulase, all known cellulases are used and are not particularly limited.

【0022】第1〜第3発明で用いられるペプチダー
ゼ、アミラーゼ、リパーゼ及びセルラーゼ等の加水分解
酵素は、患者に対しアレルゲンとして作用しないことが
必要である。
The hydrolyzing enzymes such as peptidase, amylase, lipase and cellulase used in the first to third inventions must not act on the patient as an allergen.

【0023】第2発明の抗アレルギー性食品組成物に適
用される蛋白質含有食品としては、特に制限されない
が、他の成分であるプロテアーゼ等の酵素が熱に弱いた
め、高温での調理を必要とする食品の場合には調理後の
蛋白質含有食品を意味する。該蛋白質含有食品は、この
条件を満たすものであれば特に限定されず、例えば牛
乳、ヨーグルト、チーズ、バターなどの乳製品、玉子焼
き、錦糸玉子、ホットケーキ、カステラなどの卵製品、
うどん、そばなどの麺類、ふりかけ、各種凍結乾燥品、
冷凍食品、おにぎり、弁当類、パン類、ハンバーガー、
フライドポテトなどのファーストフード、ビスケット、
チョコレートなどの菓子類などが挙げられる。また、蛋
白質含有食品には、飲料も含まれる。さらに、プロテア
ーゼ等の酵素は、溶解状態でもよく、粉末、顆粒などの
固体状態で食品組成物中に混合されていてもよい。
The protein-containing food applied to the antiallergic food composition of the second invention is not particularly limited, but requires cooking at a high temperature because enzymes such as proteases, which are other components, are weak to heat. In the case of food that does, it means a protein-containing food after cooking. The protein-containing food is not particularly limited as long as it satisfies this condition, for example, milk products, yogurt, cheese, dairy products such as butter, eggs, fried eggs, kinshi eggs, hot cakes, egg products such as castella,
Noodles such as udon, soba, sprinkle, various freeze-dried products,
Frozen foods, rice balls, lunches, breads, burgers,
Fast food such as french fries, biscuits,
Confectionery such as chocolate. The protein-containing food also includes a beverage. Further, the enzyme such as a protease may be in a dissolved state, or may be mixed in the food composition in a solid state such as a powder or a granule.

【0024】第3発明の食品用添加剤は、結果として蛋
白質などのアレルゲンを含む食品とともに患者に摂取さ
れるものであれば、食品に添加して摂取してもよく、又
は食品とは別に摂取され、患者の体内で一緒になっても
よい。
The food additive of the third invention may be added to the food or taken separately from the food as long as it is taken by the patient together with the food containing the allergen such as protein. And may be together within the patient's body.

【0025】食品添加剤は、粉末状、顆粒状、スティッ
ク状、板状などの任意の形状を取ることができ、好まし
くは顆粒状である。
The food additive can take any shape such as a powder, a granule, a stick, and a plate, and is preferably a granule.

【0026】第1〜第3発明において、(1)プロテア
ーゼ及び任意成分である(2)アミラーゼ、リパーゼ及
びセルラーゼからなる群から選ばれる少なくとも1種
は、食物と同時に又は食物と相前後して摂取されるの
が、アレルゲンの分解除去の観点から好ましい。これら
酵素は、摂取される食物量にもよるが、成人1人当たり
通常1回の食事当たり5000〜50mg程度、好まし
くは1500〜200mg程度摂取ないし投与される。
In the first to third aspects of the present invention, at least one selected from the group consisting of (1) protease and optional component (2) amylase, lipase and cellulase is ingested at the same time as or simultaneously with food. Is preferable from the viewpoint of decomposing and removing allergens. These enzymes are usually taken or administered in an amount of about 5,000 to 50 mg, preferably about 1,500 to 200 mg, per meal per adult, depending on the amount of food taken.

【0027】第1発明の抗アレルギー剤又は抗アレルギ
ー剤組成物は、経口投与用の固形ないし液体製剤として
投与される。
The antiallergic agent or antiallergic composition of the first invention is administered as a solid or liquid preparation for oral administration.

【0028】該固形製剤としては、錠剤、カプセル剤、
顆粒剤、粉末剤、丸剤等が挙げられ、液体製剤として
は、懸濁剤、乳剤が挙げられる。これら各種の製剤に
は、酵素製剤に用いられる公知の添加剤、例えばアレル
ゲンとして作用しない赤色3号、青色1号、黄色5号な
どの色素、エチルバニリンなどの香料を添加することが
できる。
As the solid preparation, tablets, capsules,
Granules, powders, pills and the like can be mentioned, and liquid preparations include suspensions and emulsions. To these various preparations, known additives used for enzyme preparations, for example, dyes such as Red No. 3, Blue No. 1 and Yellow No. 5, which do not act as allergens, and fragrances such as ethyl vanillin can be added.

【0029】[0029]

【発明の効果】本発明によれば、食物と同時に又は相前
後して、プロテアーゼおよび必要に応じて他の加水分解
酵素を摂取することにより、アトピー性皮膚炎などの食
品アレルギーを治療ないし予防することができる。特
に、本発明によれば、原因となる食品が特定されないケ
ースや、複数の食品が関連する食品アレルギーであって
も、プロテアーゼ等の加水分解酵素を摂取しさえすれば
よく、食品からアレルゲンの除去を試みる従来の手法よ
りも利用価値が高い。
According to the present invention, a food allergy such as atopic dermatitis is treated or prevented by ingesting a protease and, if necessary, other hydrolytic enzymes simultaneously with or before or after food. be able to. In particular, according to the present invention, in cases where the causal food is not specified, or even in the case of a food allergy involving a plurality of foods, it is only necessary to ingest a hydrolase such as a protease, and to remove allergens from the food. Is more valuable than traditional approaches that attempt

【0030】[0030]

【実施例】以下、本発明を実施例に基づいて説明する
が、本発明はこれら実施例に限定されるものではない。
EXAMPLES Hereinafter, the present invention will be described based on examples, but the present invention is not limited to these examples.

【0031】実施例1 RAST法による食物アレルゲン陽性の慢性じんま疹の
患者2名(4歳の男児及び4歳の女児)に、食事と共に
1日当たり下記の量のパンクレアチン、リパーゼ、ビオ
ジアスターゼおよびセルラーゼを含む酵素製剤を3回に
分けて1カ月ないし3カ月投与した。結果を以下の表1
に示す。
EXAMPLE 1 Two patients (four-year-old boy and four-year-old girl) with food allergen-positive chronic urticaria by the RAST method were given the following amounts of pancreatin, lipase, biodiastase and The enzyme preparation containing cellulase was administered in three divided doses for one to three months. The results are shown in Table 1 below.
Shown in

【0032】[0032]

【表1】 患者 投与量 投与期間 好酸球(%) 改善度 4歳女児 0.6g/日 3カ月 11→5 著明改善 4歳男児 0.6g/日 1カ月 1.8→1.7 著明改善 以上のように、皮膚の掻痒、紅斑が著明に改善された。[Table 1] Patient dose Administration period Eosinophil (%) Improvement 4-year-old girl 0.6 g / day 3 months 11 → 5 Remarkable improvement 4-year-old boy 0.6 g / day 1 month 1.8 → 1.7 Remarkable improvement In addition, itching and erythema of the skin were remarkably improved.

【0033】表1の結果から、本発明の抗アレルギー剤
ないし食品用添加剤は、慢性じんま疹の治療に有効であ
ることが明らかになった。
From the results shown in Table 1, it was revealed that the antiallergic agent or food additive of the present invention is effective for treating chronic urticaria.

【0034】実施例2 RAST法による食物アレルゲン陽性のアトピー性皮膚
炎患者2名(6歳の男児及び3歳の男児)に、食事と共
に1日当たり3錠ないし0.6gの実施例1で用いた顆粒状
の酵素製剤を3回に分けて3カ月投与した。結果を以下
の表2に示す。
Example 2 Two tablets (a 6-year-old boy and a 3-year-old boy) of atopic dermatitis positive for food allergens by the RAST method were used in combination with meals at a dose of 3 tablets to 0.6 g per day of granules used in Example 1. The enzyme preparation was administered in three divided doses for three months. The results are shown in Table 2 below.

【0035】[0035]

【表2】 患者 投与量 投与期間 好酸球(%) 改善度 6歳男児 3錠/日 3カ月 13.1→5.9 著明改善 3歳男児 0.6g/日 3カ月 10→4 著明改善 以上のように、皮膚の掻痒、紅斑が著明に改善された。[Table 2] Patient dose Administration period Eosinophil (%) Improvement 6-year-old boy 3 tablets / day 3 months 13.1 → 5.9 Remarkable improvement 3-year-old boy 0.6 g / day 3 months 10 → 4 Remarkable improvement In addition, itching and erythema of the skin were remarkably improved.

【0036】表2の結果から、本発明の抗アレルギー剤
ないし食品用添加剤は、アトピー性皮膚炎の治療に有効
であることが明らかになった。
From the results shown in Table 2, it was revealed that the antiallergic agent or food additive of the present invention is effective for treating atopic dermatitis.

フロントページの続き (56)参考文献 特開 昭57−206623(JP,A) 特開 昭60−8227(JP,A) 特開 平3−219871(JP,A) 特開 平4−103535(JP,A) 特開 平4−248959(JP,A) 米国特許4591504(US,A) 国際公開83/2724(WO,A)Continuation of the front page (56) References JP-A-57-206623 (JP, A) JP-A-60-8227 (JP, A) JP-A-3-219871 (JP, A) JP-A-4-103535 (JP) JP-A-4-248959 (JP, A) U.S. Pat. No. 4,591,504 (US, A) WO 83/2724 (WO, A)

Claims (6)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】プロテアーゼ、アミラーゼ、リパーゼ及び
セルラーゼを有効成分とする抗アレルギー剤。
1. An anti-allergic agent comprising protease, amylase, lipase and cellulase as active ingredients.
【請求項2】プロテアーゼ、アミラーゼ、リパーゼ及び
セルラーゼ並びに蛋白質含有食品を含むアレルギー対応
食品組成物。
2. An allergic food composition comprising a protease, amylase, lipase and cellulase and a protein-containing food.
【請求項3】プロテアーゼ、アミラーゼ、リパーゼ及び
セルラーゼを有効成分とするアレルギー対応食品用添加
剤。
3. An allergic food additive comprising protease, amylase, lipase and cellulase as active ingredients.
【請求項4】(1)プロテアーゼおよび(2)アミラー
ゼ、リパーゼ及びセルラーゼからなる群から選ばれる少
なくとも1種を含むアトピー性皮膚炎予防乃至治療剤。
4. A preventive or therapeutic agent for atopic dermatitis comprising (1) a protease and (2) at least one selected from the group consisting of amylase, lipase and cellulase.
【請求項5】(1)プロテアーゼおよび(2)アミラー
ゼ、リパーゼ及びセルラーゼからなる群から選ばれる少
なくとも1種並びに(3)蛋白質含有食品を含むアトピ
ー性皮膚炎対応食品組成物。
5. A food composition for atopic dermatitis comprising (1) a protease and (2) at least one selected from the group consisting of amylase, lipase and cellulase and (3) a protein-containing food.
【請求項6】(1)プロテアーゼおよび(2)アミラー
ゼ、リパーゼ及びセルラーゼからなる群から選ばれる少
なくとも1種を有効成分とするアトピー性皮膚炎対応食
品用添加剤。
6. An additive for atopic dermatitis-compatible foods comprising as active ingredients at least one selected from the group consisting of (1) protease and (2) amylase, lipase and cellulase.
JP7034127A 1995-02-22 1995-02-22 Allergy remedies and allergic foods Expired - Fee Related JP2711436B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP7034127A JP2711436B2 (en) 1995-02-22 1995-02-22 Allergy remedies and allergic foods

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7034127A JP2711436B2 (en) 1995-02-22 1995-02-22 Allergy remedies and allergic foods

Publications (2)

Publication Number Publication Date
JPH08225460A JPH08225460A (en) 1996-09-03
JP2711436B2 true JP2711436B2 (en) 1998-02-10

Family

ID=12405576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7034127A Expired - Fee Related JP2711436B2 (en) 1995-02-22 1995-02-22 Allergy remedies and allergic foods

Country Status (1)

Country Link
JP (1) JP2711436B2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3727438B2 (en) * 1997-03-31 2005-12-14 独立行政法人科学技術振興機構 Preparation method of allergenized flour, reduced allergenized flour and its processing
EP1733618A1 (en) * 2002-08-28 2006-12-20 KAPITZ, Carl-Heinz Use of an active agent for the inhibition of mould spores
FR2966734B1 (en) 2010-10-29 2014-07-18 Max Rombi COMPOSITION COMPRISING AT LEAST ONE PROTEOLYTIC ENZYME FOR ITS USE TO PREVENT THE SYNTHESIS OF TRIGLYCERIDES
JP6263540B2 (en) 2012-09-19 2018-01-17 グレスポ・アクチボラゲットGrespo AB Composition for improving brain function
WO2017057455A1 (en) * 2015-09-29 2017-04-06 株式会社カネカ Fermented food composition production method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4591504A (en) 1982-05-31 1986-05-27 Mochida Pharmaceutical Co., Ltd. Human leucocyte pepsin-like enzyme as a therapeutic agent for treating allergic disorders and immune complex diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57206623A (en) * 1981-06-04 1982-12-18 Mochida Pharmaceut Co Ltd Remedy for allergic disease
JPS608227A (en) * 1983-06-28 1985-01-17 Kaken Pharmaceut Co Ltd Antiallergic enhancer
JP2929392B2 (en) * 1989-11-02 1999-08-03 アース製薬株式会社 Serine protease
JP2952692B2 (en) * 1990-08-24 1999-09-27 株式会社林原生物化学研究所 Solid mouth material and method for producing the same
JP2648243B2 (en) * 1991-01-30 1997-08-27 森永乳業株式会社 Oligopeptide mixture and method for producing the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4591504A (en) 1982-05-31 1986-05-27 Mochida Pharmaceutical Co., Ltd. Human leucocyte pepsin-like enzyme as a therapeutic agent for treating allergic disorders and immune complex diseases

Also Published As

Publication number Publication date
JPH08225460A (en) 1996-09-03

Similar Documents

Publication Publication Date Title
US20220273777A1 (en) Methods of treating celiac disease
US20220347101A1 (en) Enzyme delivery systems and methods of preparation and use
Hausch et al. Intestinal digestive resistance of immunodominant gliadin peptides
CN101668518B (en) A lactase formulation
JP6596024B2 (en) Composition
JP2711436B2 (en) Allergy remedies and allergic foods
US20170000830A1 (en) Compositions for Relieving the Symptoms of Gluten Sensitivity and Methods of Use Thereof
Maity et al. Alkalihalobacillus clausii 088AE as a functional and medical food ingredient: assessment of in vitro protein digestibility and food calorie reduction
JP7417228B2 (en) Preventive agents for egg allergy, etc. and food compositions containing the same
JPH04320650A (en) Hydrolyzed-milk peptide excellent in emulsifying properties and low in allergic properties
TW201642882A (en) Nutrient tonic containing bee larvae
AU2015215910B2 (en) Enzyme delivery systems and methods of preparations and use
JP4344039B2 (en) Dream Accelerator
WO2023034592A1 (en) Fungal enzyme mixtures and uses thereof
JP2022093945A (en) Agent for increasing b-cell counts
Las PC Digestive Enzymes
WO2008104867A1 (en) High calorie and easily digestible food
AU2016202521A1 (en) Enzyme delivery systems and methods of preparations and use
JPH04202135A (en) Agent inhibiting enzyme inhibitor
JP2017504581A (en) Medicaments and methods for treating innate immune response diseases
AU2013224726A1 (en) Enzyme delivery systems and methods of preparations and use

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071031

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081031

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091031

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091031

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101031

Year of fee payment: 13

LAPS Cancellation because of no payment of annual fees